Ipsen: targets raised for 2024

(CercleFinance.com) - On the back of a good Q3 performance, Ipsen has again raised its targets for 2024, now targeting an operating margin of over 31% of sales (instead of 'over 30%').


Similarly, the pharmaceutical company now anticipates sales growth at constant exchange rates (CER) of over 8% (instead of 'over 7%'), but with an additional unfavorable currency impact of around 1.5%.

For the first nine months of the year, Ipsen posted sales of just under E2.5bn, up 8.1% as reported and up 9.2% at constant exchange rates (including +5.8% in oncology, +11.8% in neuroscience and +71.3% in rare diseases).

It highlights significant performances by Dysport, Cabomety and Bylvay, solid sales by Somatuline, and a growing contribution from the launches of Iqirvo in PBC and Onivyde in metastatic pancreatic ductal adenocarcinoma.


Copyright (c) 2024 CercleFinance.com. All rights reserved.